| Dr Michael Mccall Jr, MD | |
|
3810 Springhurst Blvd, Suite 200, Louisville, KY 40241 | |
| (502) 322-1946 | |
| (502) 329-8184 |
| Full Name | Dr Michael Mccall Jr |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 14 Years |
| Location | 3810 Springhurst Blvd, Louisville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1073837845 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 47190 (Kentucky) | Primary |
| 207ND0101X | Dermatology - Mohs-micrographic Surgery | 47190 (Kentucky) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Associates In Dermatology, Pllc | 1658263876 | 32 |
| Associates In Dermatology, Pllc | 1658263876 | 32 |
News Archive
"Representatives from more than 100 governments around the world, health experts, civil society organizations and other stakeholders are converging in Rio de Janeiro, Brazil for three days" at the WHO-convened World Conference on Social Determinants of Health "to discuss how social, economic and environmental conditions could be improved to reduce the health gaps within and between countries," a WHO press release states.
Children's National Medical Center has received a five-year grant from the National Institutes of Health to identify reliable early signs of prenatal brain injury caused by congenital heart disease. Catherine Limperopoulos, PhD, Director of the Advanced Pediatric Brain Imaging Research Laboratory at Children's National will lead the study.
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
Many tourists returning from India were found colonized with multidrug-resistant superbugs. Microbiologists at the Institute for Infectious Diseases of the University of Bern, Switzerland, also isolated a strain possessing a gene which can make these life-threatening bacteria resistant to the last active antibiotic option.
An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers.
› Verified 3 days ago
| Entity Name | Associates In Dermatology, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629083399 PECOS PAC ID: 1658263876 Enrollment ID: O20040325000047 |
News Archive
"Representatives from more than 100 governments around the world, health experts, civil society organizations and other stakeholders are converging in Rio de Janeiro, Brazil for three days" at the WHO-convened World Conference on Social Determinants of Health "to discuss how social, economic and environmental conditions could be improved to reduce the health gaps within and between countries," a WHO press release states.
Children's National Medical Center has received a five-year grant from the National Institutes of Health to identify reliable early signs of prenatal brain injury caused by congenital heart disease. Catherine Limperopoulos, PhD, Director of the Advanced Pediatric Brain Imaging Research Laboratory at Children's National will lead the study.
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
Many tourists returning from India were found colonized with multidrug-resistant superbugs. Microbiologists at the Institute for Infectious Diseases of the University of Bern, Switzerland, also isolated a strain possessing a gene which can make these life-threatening bacteria resistant to the last active antibiotic option.
An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Michael Mccall Jr, MD Po Box 950132, Louisville, KY 40295-0132 Ph: (888) 980-8992 | Dr Michael Mccall Jr, MD 3810 Springhurst Blvd, Suite 200, Louisville, KY 40241 Ph: (502) 322-1946 |
News Archive
"Representatives from more than 100 governments around the world, health experts, civil society organizations and other stakeholders are converging in Rio de Janeiro, Brazil for three days" at the WHO-convened World Conference on Social Determinants of Health "to discuss how social, economic and environmental conditions could be improved to reduce the health gaps within and between countries," a WHO press release states.
Children's National Medical Center has received a five-year grant from the National Institutes of Health to identify reliable early signs of prenatal brain injury caused by congenital heart disease. Catherine Limperopoulos, PhD, Director of the Advanced Pediatric Brain Imaging Research Laboratory at Children's National will lead the study.
Daiichi Sankyo Company, Limited and ArQule, Inc. today announced that the first patient has been enrolled in the Phase 3 trial of ARQ 197, an investigational selective inhibitor of the c-Met receptor tyrosine kinase, in combination with erlotinib, for patients diagnosed with non-squamous, non-small cell lung cancer (NSCLC) who have received one or two prior systemic anti-cancer therapies.
Many tourists returning from India were found colonized with multidrug-resistant superbugs. Microbiologists at the Institute for Infectious Diseases of the University of Bern, Switzerland, also isolated a strain possessing a gene which can make these life-threatening bacteria resistant to the last active antibiotic option.
An innovative approach using a tetanus booster to prime the immune system enhances the effect of a vaccine therapy for lethal brain tumors, dramatically improving patient survival, according to a study led by Duke Cancer Institute researchers.
› Verified 3 days ago
Mrs. Jyoti B. Burruss, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3810 Springhurst Blvd, Suite 200, Louisville, KY 40241 Phone: 502-583-1749 Fax: 502-329-8184 | |
Dr. Jae Yeon Jung, M.D., PH.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3810 Springhurst Blvd Ste 200, Louisville, KY 40241 Phone: 502-583-1749 Fax: 502-329-8184 | |
Vilma C Fabre, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2211 Greene Way, Ste 100, Louisville, KY 40220 Phone: 502-495-1162 Fax: 502-495-0156 | |
Elizabeth Veasey, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 800 Zorn Ave, Louisville, KY 40206 Phone: 502-287-4000 | |
Andrea S Burch, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2307 Greene Way Ste C, Louisville, KY 40220 Phone: 502-806-3376 Fax: 502-213-3999 | |
Dr. Steven J Hodge, MD Dermatology Medicare: Medicare Enrolled Practice Location: 310 E Broadway, Ste 200, Louisville, KY 40202 Phone: 502-585-5249 Fax: 502-585-5251 |